Short Communication

In Vivo Magnetic Resonance Imaging to Detect Biliary Excretion of 19F-Labeled Drug in Mice

Received November 18, 2010; accepted January 26, 2011

ABSTRACT:

Isoflurane is an inhaled halogenated hydrocarbon anesthetic commonly used for animal research. In our quest to develop a method for measuring bile acid transport in live animals using 19F magnetic resonance (MR) imaging, it occurred to us that isoflurane, which contains five fluorines per molecule and is probably widely distributed, would provide an excellent test drug to evaluate the merits of this approach. Experiments in 20- to 28-g male C57BL/6 mice were performed using a horizontal bore scanner with a 30-mm 19F/1H dual-tuned surface coil used to transmit and receive radiofrequency signals at 300.28 MHz for 1H and 282.55 MHz for 19F nuclei. Proton MR imaging was used to identify the mouse gallbladder in vivo, which was verified by anatomical dissection. Subsequent experiments in mice inhaling 1.5% isoflurane for 1 to 2 h revealed robust 19F signals from the gallbladder, verified by overlying 1H and 19F signals. No 19F signal was detected in mice anesthetized with nonhalogenated anesthetics. The presence of isoflurane in gallbladder bile of isoflurane-treated mice was verified using liquid chromatography-mass spectrometry. Gallbladder bile isoflurane content ranged from 3.2 to 4.7 μg. The data presented here provide proof of concept that this novel approach can be used for in vivo measurement of biliary excretion of both existing and novel 19F-labeled drugs.

Introduction

In the course of studying bile acid transport using an in vitro assay system, we observed that many commonly used drugs inhibit the function of the major intestinal bile acid transporter, the apical sodium-dependent bile acid transporter (ASBT) (gene name SLC10A2) (Zheng et al., 2009). These ASBT inhibitors include HMG-CoA inhibitors (statins) and dihydropyridine calcium-channel blockers; statins and calcium-channel blockers are among the most commonly prescribed drugs in the United States. Inhibition of the ASBT results in reduced intestinal uptake of bile acids and increased fecal bile acid concentrations, risk factors for colon pathology, including cancer (Flynn et al., 2007). Hence, side effects deriving from drug-induced inhibition of the ASBT could pose potential, currently unappreciated, risk.

On the basis of these observations we decided to develop a new in vivo assay to measure the ability of drugs to inhibit bile acid transport. Currently available methods to measure bile acid transport in vivo are limited to 75Se-25-homocholic acid-taurine (Boyd et al., 1981; Fracchia et al., 1998) and luciferase-farnesoid X receptor imaging (Houten et al., 2007). Hence, to measure in vivo bile acid transport we conceived an innovative, nonradioactive approach: 19F-labeled bile acid tracers and in vivo magnetic resonance imaging (MRI) in mice.

19F is particularly well suited for monitoring distribution of administered agents; 19F is second only to 1H in sensitivity for MRI, and background 19F signals in animals and humans are negligible (Jiang et al., 2009). Positron emission tomography was considered but rejected for this purpose because positron emission tomography probes are radioactive (e.g., 18F), are more costly (a cyclotron is needed to create 18F for each use), and have short radiation half-lives (109 min for 18F). In mice, stable nonradioactive 19F-labeled tracers can be imaged for days (Jiang et al., 2009).

Before we proceeded with the complex and time-consuming development of 19F-labeled bile acid tracers, several key issues had to be addressed. First, for reasons of cost and efficiency, an animal model is needed to measure bile acid uptake by in vivo MRI. After excretion from the liver, bile acids are stored and concentrated in the gallbladder. Hence, gallbladder imaging would be most likely to result in a 19F signal of sufficient strength for detection. Because rats lack a gallbladder, mice would serve this purpose and were previously used as test animals for studies of bile acid transport (Dawson et al., 2003). Second, a fluoridated test agent was required to validate the approach. Fluoridated hydrocarbons, particularly 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane (isoflurane) (Fig. 1), are commonly used to anesthetize mice, and wide tissue distribution, as well as limited hepatic metabolism of this agent, was reported (Kharasch and Walters, 2009), and its production was recently discontinued by the supplier (European Amersham catalogs). Luciferase-farnesoid X receptor imaging is applicable only in transgenic mice expressing the reporter gene and provides very limited anatomical detail (Houten et al., 2007). Hence, to measure in vivo bile acid transport we conceived an innovative, nonradioactive approach: 19F-labeled bile acid tracers and in vivo magnetic resonance imaging (MRI) in mice.

This work was supported by the National Institutes of Health National Cancer Institute [Grant CA120407]; the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grants DK67530, DK067872, DK081479]; and the National Institutes of Health National Center for Research Resources [Grant 1S10-RR019935].

ABBREVIATIONS: ASBT, apical sodium-dependent bile acid transporter; MRI, magnetic resonance imaging; LC, liquid chromatography; MS, mass spectrometry; ACN, acetonitrile.
isoﬂurane (Kharasch and Thummel, 1993). Almost 30 years ago, it was shown that high-resolution \(^{19}\)F magnetic resonance spectra from isoflurane could be obtained from a surface coil centered over the brain of a living rabbit (Wyrwicz et al., 1983).

Therefore, in the present study, we investigated whether isoﬂurane could be measured in mouse gallbladder bile using in vivo MRI. To verify the presence of isoﬂurane in gallbladder bile and estimate the limits of detection, we used liquid chromatography-mass spectrometry (LC-MS). The data presented here provide proof of concept that this novel approach can be used for in vivo measurement of biliary excretion of both existing and novel \(^{19}\)F-labeled drugs.

Materials and Methods

**Animals.** All animal studies were conducted in accordance with the *Guide for the Care and Use of Laboratory Animals* prepared by the U.S. National Academy of Sciences (National Institutes of Health publication 86-23, revised 1985). Mouse studies were approved by both the institutional animal care and use committee at the University of Maryland School of Medicine (Baltimore, MD) and the research and development committee at the VA Maryland Health Care System (Baltimore, MD). C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and housed under identical conditions in a pathogen-free environment with a 12-h light/dark cycle and free access to standard mouse chow and water for 1 week before treatment. Mice were fasted overnight before imaging studies.

**Live Animal MRI.** In vivo experiments were performed on a BioSpec 7.0-T 30-cm horizontal bore scanner using Paravision 5.0 software (Bruker Biospin MRI GmbH, Rheinstetten, Germany). A Bruker 30-mm \(^{19}\)F/\(^{1}\)H dual-tuned surface coil was used to transmit and receive radiofrequency signals at 300.28 MHz for \(^{1}\)H and 282.55 MHz for \(^{19}\)F nuclei. Mice (male C57BL/6; 20–28 g b.wt.) were anesthetized in an animal chamber with a gas mixture of \(O_2\) (1 l/min) and isoﬂurane (3%; IsoFlo; Abbott Laboratories, North Chicago, IL). Animals were then placed supine in a Bruker animal bed, and the radiofrequency coil was positioned and fixed with surgical tape in the region of interest on the animal body. The animal bed was moved to the center of the magnet, and the isoﬂurane level was changed to 1.5% and maintained at this level for the remainder of the experiment. A magnetic resonance-compatible small-animal monitoring and gating system (SA Instruments, Inc., New York, NY) was used to monitor animal respiration rate and body temperature. Mouse body temperature was maintained at 36–37°C using a warm water circulator.

The gallbladder was localized by first obtaining images using \(^{1}\)H MRI. Three-slice (axial, midsagittal, and coronal) scout rapid acquisition with fast low-angle shot MRI was used to first localize the volume of interest. High-resolution proton density-weighted anatomical images were acquired using a rapid acquisition with relaxation enhancement sequence in the axial view with repetition time of 1847 or 2631 ms, echo time of 11 ms, slice thickness of 1 mm, matrix size of 400 x 400, and in-plane resolution of 0.15 x 0.15 mm\(^2\). Number of slices was 12 or 24, and number of averages was 8. Total acquisition time was not more than 18 min.

Low-resolution \(^{19}\)F images were acquired using a fast low-angle shot sequence in the same region of the anatomical \(^{1}\)H MRI with repetition time of 123 or 245 ms, echo time of 6 ms, excitation pulse angle of 30°, field of view of 6 x 6 mm\(^2\), matrix size of 32 x 32, in-plane resolution of 1.875 x 1.875 mm\(^2\), and slice thickness of 4 mm. Number of slices was 3 or 6, and number of averages was from 600 to 1200. Total acquisition time was less than 2 h and 36 min. Mice inhaled isoﬂurane from 50 to 94 min before \(^{19}\)F MRI experiments.

**Liquid Chromatography-Mass Spectrometry.** In parallel studies, to measure the isoﬂurane content in gallbladder bile, mice were dosed with isoﬂurane using the same protocol described for live animal MRI. Mice were euthanized immediately after completion of isoﬂurane inhalation, and the gallbladders were removed and weighed. Tissue samples were transported in tightly sealed containers with minimal head space and stored on ice before sample preparation. The gallbladder was ground using a tissue homogenizer in the presence of 75:25 acetonitrile (ACN)-water solvent. Homogenized tissue was centrifuged (9600 g for 1 min at 4°C), and the isoﬂurane content of the supernatant was measured using LC-MS. LC-MS was performed using a TSQ Vantage (Thermo Fisher Scientific, Waltham, MA) mass spectrometer, with an Accela 1250 pump and a PAL HTC-Accela TM autosampler. The column was a Gemini C18 (50 x 4.6 mm, 3 μm, 110 Å; Phenomenex, Torrance, CA). The mobile phase (1.2 ml/min, water and ACN) was a gradient as follows: 0 to 0.5 min, 40% ACN; 0.5 to 1.5 min, 40 to 95% ACN; 1.5 to 2.5 min, 95% ACN; 2.5 to 2.6 min, 95 to 40% ACN; and 2.6 to 3.6 min, 40% ACN. MS was performed using an atmospheric pressure chemical ionization probe in negative mode; ion transition \(m/z\) 183 \(\rightarrow\) 163 was used to quantify isoﬂurane. Data collection and processing were performed using Xcalibur 2.3.0 with LCquan 2.6.0 software (see Table 1).

![Fig. 1.](Image) The chemical structure of 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane (isoﬂurane) highlighting the five fluorines, including the three equivalent fluorines bonded to the ethane portion.

![A](Image) ![B](Image) FIG. 2. Localization of the mouse gallbladder by live animal MRI and verification by anatomical dissection. A, high-resolution proton density-weighted anatomical image of the murine gallbladder (arrowhead) acquired using live animal MRI as described under Materials and Methods. B, gallbladder location (arrow) and appearance were verified by dissection immediately after liver animal MRI. The mouse gallbladder, just to the left of midline, is attached superiorly by the falciform ligament. It is likely that the gallbladder appears less distended than in the magnetic resonance image because of the effects of ketamine/xylazine anesthesia, given after the effects of isoﬂurane had abated, and as a consequence of surgical manipulation and stretching of the gallbladder to obtain the photograph.
Results and Discussion

Exhalation is the major route of elimination for halogenated hydrocarbon anesthetics such as isoflurane (Fig. 1). On the basis of both existing and novel19F-labeled drugs. 

not shown). This localization of the19F signal in the gallbladder suggests that isoflurane is distributed into bile.

To assess19F MRI results, parallel studies using LC-MS to measure isoflurane were performed in five mice. Four mice were treated with inhaled isoflurane as described under Materials and Methods, and one control mouse received subcutaneous nonhalogenated anesthetics (no isoflurane). As an unplanned control, the gallbladder of one of the four isoflurane-treated mice was emptied of bile before removal, such that no isoflurane was detected in that mouse.

Table 1 lists the amount of isoflurane in each mouse gallbladder. No isoflurane was found in gallbladders from the two control mice: one that did not receive isoflurane and one whose gallbladder was emptied before the assay. In the remaining three isoflurane-treated mice, 4.72, 3.25, and 3.52 μg of isoflurane was detected in the gallbladder (mean ± S.E., 3.83 ± 0.45 μg) (Table 1). Although the volume of gallbladder contents was not measured, we estimated the isoflurane concentration in gallbladder bile on the basis of published data relating gallbladder volume to mouse weight (Graewin et al., 2004). This analysis yielded gallbladder bile isoflurane concentrations of 2.2, 1.3, and 1.4 mM, respectively (Table 1), suggesting that the limits of detection for isoflurane using19F MRI are at least 1 to 2 mM.

Regarding the use of this approach for measuring bile acid transport, an advantage of MRI of the gallbladder is that bile acids are stored in this organ. It is estimated that after an overnight fast, at least 80% of the bile acid pool is stored in the gallbladder (Nilsell, 1990). The amount of19F-labeled bile acid tracer that accumulates in the mouse gallbladder during an overnight fast will depend on the test dose, stability, absorption, mouse body weight, and other factors. Nonetheless, using conservative estimates, we calculate that gavaging mice with19F-labeled chenodeoxycholic acid (15–300 μg/g b.w.t.) will result in ~2 to 15 mM 19F-labeled bile acid in the gallbladder (assuming that ~50% of19F-labeled bile acid accumulates in the gallbladder, volume ~20 μl). These values are above the limits of detection for isoflurane in the present communication (1–2 mM).

In summary, mice inhaling 1.5% isoflurane for 1 to 2 h revealed robust19F signals in the gallbladder, verified by overlying1H and19F signals. No19F signal was detected in mice anesthetized with nonhalogenated agents. The presence of isoflurane in gallbladder bile of isoflurane-treated mice was confirmed using LC-MS; isoflurane content ranged from 3.2 to 4.7 μg. This finding demonstrates the sensitivity of19F MRI; the level of detection is at least 1 to 2 mM. The data presented here provide an important proof of concept that this novel approach can be used for in vivo measurement of biliary excretion of both existing and novel19F-labeled drugs.

TABLE 1

<table>
<thead>
<tr>
<th>Gallbladder Weight</th>
<th>Gallbladder Isoflurane</th>
<th>Calculated Isoflurane Conc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>No isoflurane control</td>
<td>4.9 µg</td>
<td>N.D.</td>
</tr>
<tr>
<td>Emptied gallbladder control</td>
<td>3.3 µg</td>
<td>N.D.</td>
</tr>
<tr>
<td>Isoflurane-treated mouse 1</td>
<td>26.0 µg</td>
<td>4.72</td>
</tr>
<tr>
<td>Isoflurane-treated mouse 2</td>
<td>12.6 µg</td>
<td>3.25</td>
</tr>
<tr>
<td>Isoflurane-treated mouse 3</td>
<td>17.3 µg</td>
<td>3.52</td>
</tr>
</tbody>
</table>

N.D., not detected.

*The calculated isoflurane concentration assumes mouse gallbladder volume of 8 μl/16 g mouse total body weight (Graewin et al., 2004).
Acknowledgments

We acknowledge Steven Roys for helping with overlay of 19F and 1H MRI images.

Departments of Medicine (J.-P.R., K.C., S.K.) and Diagnostic Radiology and Nuclear Medicine (S.X., D.S., R.G.), School of Medicine, and the Department of Pharmaceutical Sciences (D.J., C.S., M.A.K., J.P.), School of Pharmacy, University of Maryland, Baltimore, Maryland

JEAN-PIERRE RAUFMAN
SU XU
KUNRONG CHENG
SANDEEP KHURANA
DIANA JOHNSON
CHANGXING SHAO
MAUREEN A. KANE
DA SHI
RAO GULLAPALLI
JAMES POLLI

Authorship Contributions

Participated in research design: Raufman, Xu, Cheng, Johnson, Gullapalli, and Polli.
Conducted experiments: Raufman, Xu, Cheng, Khurana, Johnson, Shao, Kane, Shi, Gullapalli, and Polli.
Contributed new reagents or analytic tools: Xu, Johnson, Shao, Kane, Shi, Gullapalli, and Polli.
Performed data analysis: Raufman, Xu, Cheng, Johnson, Shao, Kane, and Polli.
Wrote or contributed to the writing of the manuscript: Raufman, Xu, Cheng, Khurana, Johnson, Gullapalli, and Polli.

References


Address correspondence to: Dr. Jean-Pierre Raufman, Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, 22 South Greene St., N3WB6, Baltimore, MD 21201. E-mail: jraufman@medicine.umaryland.edu